Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for Ferrous Gluconate

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive, prevented essentially all sperm from entering the cervical canal across all women and all cycles evaluated.


Lead Product(s): Ferrous Gluconate,Ascorbic Acid

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Bayer AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 10, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Daré and Avomeen are currently collaborating on development-stage programs, including Ovaprene®, an investigational hormone-free, monthly contraceptive, and intend to expand their partnership to include more programs in Daré’s women’s health pipeline.


Lead Product(s): Ferrous Gluconate,Ascorbic Acid

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Avomeen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 01, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Publication of a literature review article by Biology of Reproduction identifies and reviews 10 postcoital test studies of vaginal contraceptives involving 9 test products, including Daré’s Ovaprene, currently under a license agreement with Bayer.


Lead Product(s): Ferrous Gluconate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY